Core Viewpoint - Psyence Biomedical Ltd. successfully held its Annual and Special Meeting of Shareholders, where shareholders approved all proposed business matters, including the election of directors and share consolidation authority [1][2]. Group 1: Shareholder Meeting Outcomes - All director nominees were elected to serve until the next annual meeting or until successors are appointed [2]. - MNP LLP was appointed as the Company's auditors for the upcoming year, with the Board authorized to determine their remuneration [2]. - Shareholders approved a special resolution allowing the Board to consolidate the Company's common shares at a ratio of up to 250:1, with the timing and ratio to be determined by the Board [2][3]. Group 2: Company Overview - Psyence Biomedical Ltd. is a biopharmaceutical company focused on developing nature-derived psilocybin and ibogaine therapies for mental health needs [4]. - The Company is recognized as the first life sciences biotechnology firm specializing in psychedelic medicine to be listed on Nasdaq [4]. - Psyence is committed to an evidence-based approach in developing safe and effective treatments for various mental health disorders [4].

Core Viewpoint - Psyence Biomedical Ltd. has entered into a Put Option Agreement with PsyLabs, positioning the company for significant future equity participation in a leading manufacturer of pharmaceutical-grade psychedelics, ensuring a reliable supply as commercialization progresses [1][3]. Group 1: Put Option Agreement Details - The Put Option Agreement allows PsyLabs to require Psyence BioMed to make further equity investments through a share-for-share exchange at fair market value, forming part of a broader strategic relationship [2][4]. - This agreement provides Psyence BioMed with a structured opportunity to acquire a significant equity stake in PsyLabs while securing a reliable supply of pharmaceutical-grade psychedelics for future clinical programs [3][4]. Group 2: Strategic and Commercial Benefits - The agreement enhances Psyence BioMed's clinical development pathway by mitigating supply-chain and regulatory risks, allowing the company to maintain financial flexibility without significant upfront capital deployment [4][5]. - PsyLabs is recognized as one of the most advanced manufacturers of pharmaceutical-grade psychedelic compounds, with expertise in scalable, GMP-compliant production [3][6]. Group 3: Company Background - Psyence Biomedical Ltd. is a vertically integrated biopharmaceutical company focused on developing nature-derived psilocybin and ibogaine therapies to address unmet mental health needs, being the first of its kind listed on Nasdaq [8]. - PsyLabs is federally licensed to cultivate and export various psychedelic compounds, including psilocybin and ibogaine, to legal medical and research markets, with successful exports to multiple countries [6][7].

Core Viewpoint - Psyence Biomedical Ltd. has established a sustainable supply of high-potency iboga bark through its partnership with PsyLabs, which is crucial for the clinical development of ibogaine for substance use disorders [1][2][4] Group 1: Supply Chain and Product Development - The collaboration with PsyLabs ensures a long-term supply of GMP-compliant ibogaine, with the first 50 kg received and being processed into pharmaceutical-grade ibogaine HCL and Total Alkaloid Extracts [2][3] - The company is committed to ethical sourcing and sustainability, ensuring that ibogaine and related alkaloids are derived from Tabernanthe iboga and Voacanga africana while respecting cultural traditions and benefiting source communities [3][4] Group 2: Strategic Positioning and Market Leadership - The establishment of a reliable and ethically sourced supply chain positions Psyence BioMed as a leader in the emerging ibogaine sector, enhancing its competitive advantage as international interest in ibogaine grows [4] - The company aims to set a new standard for ethical psychedelic production, emphasizing partnerships with traditional knowledge holders rather than treating them merely as suppliers [4][6] Group 3: Company Overview - Psyence Biomedical Ltd. is a vertically integrated biopharmaceutical company focused on developing nature-derived psilocybin and ibogaine-based psychedelic medicine, addressing unmet mental health needs [6] - The company is the first life sciences biotechnology firm specializing in psychedelic therapeutics to be listed on Nasdaq, reflecting its commitment to an evidence-based approach in developing safe and effective treatments [6]